Johnson & Johnson Unit to Contest Record $1.6 Billion False Claims Act Ruling

Johnson & Johnson Unit Fights Record $1.6 Billion False Claims Act Judgment

Janssen Products LP, a Johnson & Johnson unit, is mounting an aggressive legal challenge against a $1.6 billion judgment in what stands as the largest False Claims Act penalty in U.S. history. The case, which centers on the company’s marketing practices for HIV drugs Prezista and Intelence, reaches a critical juncture as the U.S. Court of Appeals for the Third Circuit in Philadelphia hears arguments this week.

The pharmaceutical giant is seeking to overturn a jury verdict that found it responsible for submitting nearly 160,000 false claims to the federal government through allegedly unlawful promotion of the antiviral medications. A federal judge in New Jersey upheld the verdict in 2025, ordering Janssen to pay $1.28 billion in penalties plus $360 million in treble damages.

The stakes are exceptionally high, not just for Janssen but for the government’s fraud enforcement efforts. The judgment represents almost one-quarter of the Justice Department’s record-breaking $6.8 billion recovery from False Claims Act suits in 2025.

The case began in 2012 when whistleblowers Jessica Penelow and Christine Brancaccio filed suit alleging that Janssen’s marketing tactics led federal healthcare programs to improperly reimburse claims for the HIV drugs. In 2021, a federal district judge allowed the case to proceed, finding the whistleblowers had sufficiently argued that Janssen’s off-label drug promotion misled doctors about the medications’ appropriateness for patients with lipid conditions.

Legal experts suggest Janssen’s strongest argument on appeal may be challenging the “materiality” requirement of the False Claims Act. “The undisputed evidence that the government has continued to pay Prezista and Intelence claims with full knowledge of the allegations is a significant challenge to the relators’ materiality case,” said Nadia Patel of ArentFox Schiff LLP.

The whistleblowers counter that they demonstrated the government wouldn’t have paid these claims had it known about the misleading drug promotion activities.

Janssen—now operating under the name Johnson & Johnson Innovative Medicine—has also raised constitutional concerns, claiming the $1.6 billion award is “astronomical” and violates the Eighth Amendment’s prohibition on excessive fines. The company argues the lower court failed to properly assess the disparity between the penalties and the benefits of its investment in lifesaving medications.

James Miller of Miller Shah LLP, who represents False Claims Act whistleblowers, believes this argument is unlikely to gain traction with the appeals court. “The penalties are within the bounds of reasonableness, as well as the statutory structure designed by Congress,” he noted.

Interestingly, the U.S. government has partially sided with Janssen on one technical aspect of the case. In its brief, the government agreed that the district court incorrectly instructed the jury regarding the element of falsity, suggesting that FDA approval of a drug for a specific usage is necessary for Medicare reimbursement.

Martin Weinstein of Cadwalader, Wickersham & Taft LLP, who represents defendants in False Claims Act cases, views this as potentially significant. “If the Third Circuit agrees that the district court gave an incorrect jury instruction by inserting the ‘on the label’ concept, that could be a strong basis for the court to question the verdict,” he explained.

The appeals court may also need to address a more fundamental constitutional question—whether whistleblowers filing lawsuits against alleged fraudsters on the government’s behalf (known as “qui tam” provisions) is constitutional at all. Janssen argues that Article II of the Constitution doesn’t permit such suits. However, legal observers note that every circuit court that has previously addressed this issue has upheld the provision.

The pharmaceutical industry is closely watching this case, as its outcome could influence how companies promote their products and interact with government healthcare programs. A reversal would represent a significant setback for whistleblower-initiated fraud enforcement, while an affirmation would reinforce the government’s aggressive stance on healthcare fraud.

The Third Circuit case is United States ex rel. Penelow v. Janssen Prods. LP, with oral arguments scheduled for March 18, 2026. Reese Marketos LLP, Kellogg Hansen, and Berger Montague PC represent the whistleblowers, while Covington & Burling LLP represents Janssen.